VOR BIOPHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.74 USD | -7.45% |
|
0.00% | -23.11% |
| Mar. 21 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
| Mar. 21 | Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 1.43M | Capitalization | 128M |
|---|---|---|---|---|---|
| Net income 2024 * | -102M | Net income 2025 * | -115M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 16.29M | Net cash position 2025 * | 52.11M | EV / Sales 2025 * | 53.3 x |
| P/E ratio 2024 * |
-1.35
x | P/E ratio 2025 * |
-1.39
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.30% | ||
| 1 week | +9.94% | ||
| Current month | -20.68% | ||
| 1 month | -2.59% | ||
| 3 months | -19.66% | ||
| 6 months | -9.62% | ||
| Current year | -16.44% |
1 week
1.66
1.95
1 month
1.662.43
Current year
1.663.14
1 year
1.625.70
3 years
1.6231.20
5 years
1.6263.62
10 years
1.6263.62
| Managers | Title | Age | Since |
|---|---|---|---|
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
Nathan Jorgensen
DFI | Director of Finance/CFO | 47 | 20-04-30 |
| Chief Tech/Sci/R&D Officer | 51 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 20-07-29 |
Matt Patterson
CHM | Chairman | 52 | 20-10-19 |
Bob Ang
CEO | Chief Executive Officer | 49 | 19-08-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.74 | -7.45% | 264 361 |
| 24-04-23 | 1.88 | +3.30% | 209,685 |
| 24-04-22 | 1.82 | +6.43% | 232,177 |
| 24-04-19 | 1.71 | +1.79% | 199,060 |
| 24-04-18 | 1.68 | -2.89% | 153,149 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.88
USD
Average target price
14.69
USD
Spread / Average Target
+681.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.44% | 128M | |
| +3.13% | 43.43B | |
| +48.49% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +32.83% | 12.59B | |
| +1.58% | 12.33B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- VOR Stock
